Harrow FY2026 EPS Forecast Increased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has increased its FY2026 earnings per share estimate for Harrow, Inc. to $2.39, up from a prior estimate of $2.12, maintaining an "Overweight" rating with a price target of $76.00.
• Harrow's stock has received multiple "buy" ratings from various brokerages, with a consensus rating of "Buy" and an average target price of $64.67.
• The company reported a quarterly earnings per share of $0.24, exceeding analyst estimates of $0.01, though it had a revenue of $63.74 million, slightly below the consensus of $64.23 million.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2026 EPS estimates for Harrow in a report issued on Wednesday, August 13th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will earn $2.39 per share for the year, up from their prior estimate of $2.12. Cantor Fitzgerald currently has a "Overweight" rating and a $76.00 target price on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million.

HROW has been the subject of several other research reports. HC Wainwright upped their price objective on Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday. BTIG Research increased their target price on shares of Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research report on Thursday. Finally, William Blair initiated coverage on shares of Harrow in a research report on Tuesday, June 10th. They set an "outperform" rating for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $64.67.

Harrow Trading Down 3.0%

Shares of Harrow stock traded down $1.19 on Thursday, hitting $38.82. The stock had a trading volume of 879,943 shares, compared to its average volume of 647,615. The stock has a 50 day moving average of $33.18 and a 200 day moving average of $28.87. Harrow has a twelve month low of $20.85 and a twelve month high of $59.23. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. The firm has a market capitalization of $1.44 billion, a P/E ratio of -155.28 and a beta of 0.41.

Institutional Trading of Harrow

Large investors have recently modified their holdings of the stock. Braidwell LP lifted its holdings in shares of Harrow by 5.5% in the 1st quarter. Braidwell LP now owns 956,839 shares of the company's stock worth $25,452,000 after purchasing an additional 49,800 shares in the last quarter. Geode Capital Management LLC lifted its stake in Harrow by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 810,803 shares of the company's stock valued at $24,765,000 after acquiring an additional 36,724 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its stake in Harrow by 6.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock valued at $22,301,000 after acquiring an additional 41,896 shares in the last quarter. Marshall Wace LLP lifted its stake in Harrow by 31.5% during the 2nd quarter. Marshall Wace LLP now owns 564,876 shares of the company's stock valued at $17,251,000 after acquiring an additional 135,202 shares in the last quarter. Finally, Voya Investment Management LLC lifted its stake in Harrow by 4,035.5% during the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock valued at $10,147,000 after acquiring an additional 372,237 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.